CE-224535 is primarily investigated for its potential therapeutic applications in the field of medicine. It is being studied as a selective antagonist for the interleukin-17 (IL-17) receptor involved in inflammatory and autoimmune diseases. Research suggests that it may play a role in modulating immune responses, making it a candidate for treating conditions such as rheumatoid arthritis, psoriasis, and other chronic inflammatory disorders. Additionally, its mechanism of action is being explored for potential benefits in pain management and neuroinflammatory conditions. Preclinical studies are ongoing to evaluate its efficacy, safety, and potential for clinical use.